Uterine artery embolization of symptomatic uterine fibroida . Initial success and short-term results

• Published in: Acta radiologica (1987) 2001-03, Vol.42 (2), p.234-238
• Main Authors: Andersen, P E, Lund, N, Justesen, P, Munk, T, Elle, B, Floridon, C
• Format: Article
• Language: English
• Subjects: Adult; Embolization, Therapeutic - adverse effects; Embolization, Therapeutic - methods; Female; Humans; Leiomyoma - therapy; Middle Aged; Treatment Outcome; Uterine Neoplasms - therapy; Uterus - blood supply
• ISSN: 0284-1851

To evaluate reduction in fibroid volume, the effect on clinical symptoms, adverse events and complications after percutaneous uterine artery embolization (UAE) as primary invasive treatment for symptomatic uterine fibroids. Sixty-two patients entered the study. Indications for treatment were fibroid-induced menorrhagia, bulk symptoms, pain, and/or large fibroid size. The first 50 patients were evaluated by clinical examination and ultrasonography with measurement of fibroid volume before treament and 1, 6 and 12 months after UAE. The remaining 12 patients were followed 3 and 12 months after treatment. Embolization with microparticles was performed percutaneously in local analgesia by selective catheterization of both uterine arteries. A primary technical success with bilateral UAE was achieved in 60/62 (97%) of the patients. They were treated for postprocedural pain lasting up to 24 h. In 30 of the 62 patients with 6 months follow-up, the mean fibroid volume was reduced 68% 6 months after treatment. Twenty-nine (96%) of the patients experienced reduced bleeding, 21 (70%) reduced pain, and 18 (61%) reduced bulk symptoms at follow-up. UAE is a method with a high technical success rate. The treatment has good effect on fibroid volume reduction and clinical symptoms. Severe post-procedural pain occurs generally in successful bilateral embolizations, but complications and adverse events are otherwise few and minor. UAE represents a promising new method for treating uterine fibroid-related symptoms.